Taysha Gene Therapies, Inc. (TSHA)

NASDAQ: TSHA · Real-Time Price · USD

4.490

-0.120 (-2.60%)

At close: Mar 13, 2026, 4:00 PM EDT

4.460

-0.030 (-0.67%)

After-hours: Mar 13, 2026, 5:44 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Developing AAV-Based Gene Therapies for The Treatment of Rare Monogenic Diseases	8.33M	15.45M	2.50M	-	-
Developing AAV-Based Gene Therapies for The Treatment of Rare Monogenic Diseases Growth	-46.07%	517.55%	-	-	-
Total	8.33M	15.45M	2.50M	-	-
Total Growth	-46.07%	517.55%	-	-	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
United States	8.33M	15.45M	2.50M	-	-
United States Growth	-46.07%	517.55%	-	-	-
Total	8.33M	15.45M	2.50M	-	-
Total Growth	-46.07%	517.55%	-	-	-

Source: S&P Global Market Intelligence.